Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (not Kiora Pharmaceuticals Inc.) on November 26, 2019. The filing addresses corporate governance and executive compensation matters, specifically the adoption of an amended change in control severance plan and an amendment to the CEO's employment agreement. The company is an emerging growth company listed on the Nasdaq Capital Market under the symbol EYEG.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on contractual and compensatory arrangements.
Material Changes
The filing details two material changes to executive compensation structures effective November 26, 2019:
- Amended and Restated Change in Control Severance Plan: The Compensation Committee adopted a plan covering all full-time employees except the CEO. It revises the definition of "Qualified Termination" to include terminations occurring after a definitive change in control agreement is executed. Severance for executives (VP level or higher) ranges from 26 to 52 weeks of base salary, while other employees receive 8 to 26 weeks. The plan also includes prorated annual incentives and six months of COBRA health coverage.
- CEO Employment Agreement Amendment: An amendment was executed with Stephen From, President and CEO. Changes include:
- Revised transaction value thresholds and severance amounts tied to the value of a change in control transaction, capped at 1.5% of the transaction value.
- Increased bonus entitlement upon termination without Cause or for Good Reason to 1.5 times the maximum performance bonus eligible for the year of termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of market risks. The stated purpose of the new severance plan is to ensure the continued dedication of employees and minimize disruption in the event of a change in control. The plan includes a "golden parachute" provision where payments subject to Section 280G of the Internal Revenue Code will be reduced unless the unreduced amount provides a greater after-tax benefit to the employee (at least 5% greater). No excise tax gross-ups are provided.
Investor Verification Checklist
- Verify the exact terms of the "Change in Control" definition in the full text of the Amended and Restated Plan (Exhibit 10.1).
- Confirm the specific transaction value thresholds triggering the CEO's 1.5% severance cap in the Employment Agreement Amendment (Exhibit 10.2).
- Review the company's most recent 10-Q or 10-K for actual financial health, as this 8-K provides no liquidity or solvency data.
- Assess the potential impact of the increased CEO bonus multiplier on future cash burn if a termination event occurs.